CytomX Therapeutics (CTMX) Asset Utilization Ratio (2015 - 2026)

CytomX Therapeutics' Asset Utilization Ratio history runs 12 years deep, the most recent figure standing at 0.14 for Q1 2026.

• Quarterly Asset Utilization Ratio fell 89.67% year-over-year to 0.14 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.14 (down 89.67% YoY) and the FY2025 annual result came in at 0.56, down 34.64% from the prior year.
• Asset Utilization Ratio was 0.14 for Q1 2026 at CytomX Therapeutics, down from 0.49 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 1.35 in Q1 2025 and bottomed at 0.12 in Q1 2022.
• A 5-year average of 0.54 and a median of 0.48 in 2023 frame the typical range for Asset Utilization Ratio.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio surged 142.48% — and 2026, when it sank 89.67%.
• CytomX Therapeutics' Asset Utilization Ratio stood at 0.22 in 2022, then soared by 119.38% to 0.48 in 2023, then jumped by 122.38% to 1.06 in 2024, then slumped by 53.78% to 0.49 in 2025, then slumped by 71.72% to 0.14 in 2026.
• Business Quant data shows CTMX's Asset Utilization Ratio at 0.14 in Q1 2026, 0.49 in Q4 2025, and 0.68 in Q3 2025.